# Bausch Health Companies Inc.: financial statements, quarterly

BHC · NYSE · CIK 885590 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bhc.md) · [Financials](/companies/bhc/financials.md) · [Filings](/companies/bhc/filings.md) · [Insiders](/companies/bhc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bhc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,238](/filings/0000885590-24-000036.md) | [2,408 d](/filings/0000885590-26-000023.md) | [2,153](/filings/0000885590-25-000020.md) | [2,403](/filings/0000885590-25-000032.md) | [2,510](/filings/0000885590-25-000051.md) | [2,559 d](/filings/0000885590-26-000023.md) | [2,259](/filings/0000885590-26-000053.md) | [2,530](/filings/0000885590-26-000107.md) | [2,681](/filings/0000885590-25-000051.md) | [2,796 d](/filings/0000885590-26-000023.md) | [2,524](/filings/0000885590-26-000053.md) | [2,852](/filings/0000885590-26-000107.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [715](/filings/0000885590-24-000036.md) | [766 d](/filings/0000885590-26-000023.md) | [794](/filings/0000885590-25-000020.md) | [832](/filings/0000885590-25-000032.md) | [850](/filings/0000885590-25-000051.md) | [820 d](/filings/0000885590-26-000023.md) | [867](/filings/0000885590-26-000053.md) | [894](/filings/0000885590-26-000107.md) | [795](/filings/0000885590-25-000051.md) | [882 d](/filings/0000885590-26-000023.md) | [861](/filings/0000885590-26-000053.md) | [907](/filings/0000885590-26-000107.md) |
| Operating income | $m | [14.0](/filings/0000885590-24-000036.md) | [362 d](/filings/0000885590-26-000023.md) | [281](/filings/0000885590-25-000020.md) | [389](/filings/0000885590-25-000032.md) | [318](/filings/0000885590-25-000051.md) | [558 d](/filings/0000885590-26-000023.md) | [276](/filings/0000885590-26-000053.md) | [444](/filings/0000885590-26-000107.md) | [619](/filings/0000885590-25-000051.md) | [474 d](/filings/0000885590-26-000023.md) | [(950)](/filings/0000885590-26-000053.md) | [740](/filings/0000885590-26-000107.md) |
| Income tax | $m | [56.0](/filings/0000885590-24-000036.md) | [40.0 d](/filings/0000885590-26-000023.md) | [8.0](/filings/0000885590-25-000020.md) | [49.0](/filings/0000885590-25-000032.md) | [71.0](/filings/0000885590-25-000051.md) | [111 d](/filings/0000885590-26-000023.md) | [39.0](/filings/0000885590-26-000053.md) | [12.0](/filings/0000885590-26-000107.md) | [37.0](/filings/0000885590-25-000051.md) | [159 d](/filings/0000885590-26-000023.md) | [77.0](/filings/0000885590-26-000053.md) | [88.0](/filings/0000885590-26-000107.md) |
| Net income | $m | [(378)](/filings/0000885590-24-000036.md) | [(39.0) d](/filings/0000885590-26-000023.md) | [(64.0)](/filings/0000885590-25-000020.md) | [10.0](/filings/0000885590-25-000032.md) | [(85.0)](/filings/0000885590-25-000051.md) | [93.0 d](/filings/0000885590-26-000023.md) | [(58.0)](/filings/0000885590-26-000053.md) | [148](/filings/0000885590-26-000107.md) | [179](/filings/0000885590-25-000051.md) | [(112) d](/filings/0000885590-26-000023.md) | [(1,423)](/filings/0000885590-26-000053.md) | [258](/filings/0000885590-26-000107.md) |
| Diluted EPS | $ per share | [(1.03)](/filings/0000885590-24-000036.md) | not reported | [(0.17)](/filings/0000885590-25-000020.md) | [0.03](/filings/0000885590-25-000032.md) | [(0.23)](/filings/0000885590-25-000051.md) | not reported | [(0.16)](/filings/0000885590-26-000053.md) | [0.40](/filings/0000885590-26-000107.md) | [0.48](/filings/0000885590-25-000051.md) | not reported | [(3.82)](/filings/0000885590-26-000053.md) | [0.68](/filings/0000885590-26-000107.md) |
| Basic EPS | $ per share | [(1.03)](/filings/0000885590-24-000036.md) | not reported | [(0.17)](/filings/0000885590-25-000020.md) | [0.03](/filings/0000885590-25-000032.md) | [(0.23)](/filings/0000885590-25-000051.md) | not reported | [(0.16)](/filings/0000885590-26-000053.md) | [0.40](/filings/0000885590-26-000107.md) | [0.48](/filings/0000885590-25-000051.md) | not reported | [(3.82)](/filings/0000885590-26-000053.md) | [0.69](/filings/0000885590-26-000107.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.8](/filings/0000885590-24-000036.md) | [0.9](/filings/0000885590-26-000023.md) | [0.7](/filings/0000885590-25-000020.md) | [0.6](/filings/0000885590-25-000032.md) | [0.7](/filings/0000885590-25-000051.md) | [1.2](/filings/0000885590-26-000023.md) | [1.1](/filings/0000885590-26-000053.md) | [1.7](/filings/0000885590-26-000107.md) | [1.3](/filings/0000885590-25-000051.md) | [1.3](/filings/0000885590-26-000107.md) | [1.3](/filings/0000885590-26-000053.md) | [1.8](/filings/0000885590-26-000107.md) |
| Current assets | $bn | [5.0](/filings/0000885590-23-000035.md) | [5.6](/filings/0000885590-25-000007.md) | [5.4](/filings/0000885590-24-000019.md) | [5.2](/filings/0000885590-24-000029.md) | [5.4](/filings/0000885590-24-000036.md) | [5.8](/filings/0000885590-26-000023.md) | [5.7](/filings/0000885590-25-000020.md) | [6.5](/filings/0000885590-25-000032.md) | [6.2](/filings/0000885590-25-000051.md) | [6.2](/filings/0000885590-26-000107.md) | [6.0](/filings/0000885590-26-000053.md) | [6.5](/filings/0000885590-26-000107.md) |
| Total assets | $bn | [27.1](/filings/0000885590-23-000035.md) | [27.4](/filings/0000885590-25-000007.md) | [26.9](/filings/0000885590-24-000019.md) | [26.5](/filings/0000885590-24-000029.md) | [26.5](/filings/0000885590-24-000036.md) | [26.5](/filings/0000885590-26-000023.md) | [26.4](/filings/0000885590-25-000020.md) | [27.3](/filings/0000885590-25-000032.md) | [26.8](/filings/0000885590-25-000051.md) | [26.4](/filings/0000885590-26-000107.md) | [24.5](/filings/0000885590-26-000053.md) | [24.8](/filings/0000885590-26-000107.md) |
| Current liabilities | $bn | [4.2](/filings/0000885590-23-000035.md) | [4.3](/filings/0000885590-25-000007.md) | [4.4](/filings/0000885590-24-000019.md) | [4.4](/filings/0000885590-24-000029.md) | [4.5](/filings/0000885590-24-000036.md) | [6.8](/filings/0000885590-26-000023.md) | [4.3](/filings/0000885590-25-000020.md) | [5.0](/filings/0000885590-25-000032.md) | [4.8](/filings/0000885590-25-000051.md) | [4.2](/filings/0000885590-26-000107.md) | [4.5](/filings/0000885590-26-000053.md) | [4.5](/filings/0000885590-26-000107.md) |
| Total liabilities | $bn | [27.3](/filings/0000885590-23-000035.md) | [27.4](/filings/0000885590-25-000007.md) | [27.1](/filings/0000885590-24-000019.md) | [26.7](/filings/0000885590-24-000029.md) | [26.8](/filings/0000885590-24-000036.md) | [26.8](/filings/0000885590-26-000023.md) | [26.7](/filings/0000885590-25-000020.md) | [27.1](/filings/0000885590-25-000032.md) | [26.5](/filings/0000885590-25-000051.md) | [26.0](/filings/0000885590-26-000107.md) | [25.6](/filings/0000885590-26-000053.md) | [25.6](/filings/0000885590-26-000107.md) |
| Long-term debt | $bn | [21.9](/filings/0000885590-23-000035.md) | [21.9](/filings/0000885590-25-000007.md) | [21.5](/filings/0000885590-24-000019.md) | [21.2](/filings/0000885590-24-000029.md) | [21.1](/filings/0000885590-24-000036.md) | [18.9](/filings/0000885590-26-000023.md) | [21.2](/filings/0000885590-25-000020.md) | [20.9](/filings/0000885590-25-000032.md) | [20.5](/filings/0000885590-25-000051.md) | [20.6](/filings/0000885590-26-000107.md) | [19.9](/filings/0000885590-26-000053.md) | [19.9](/filings/0000885590-26-000107.md) |
| Current portion of debt | $bn | [0.5](/filings/0000885590-23-000035.md) | [0.5](/filings/0000885590-25-000007.md) | [0.5](/filings/0000885590-24-000019.md) | [0.5](/filings/0000885590-24-000029.md) | [0.5](/filings/0000885590-24-000036.md) | [2.7](/filings/0000885590-26-000023.md) | [0.3](/filings/0000885590-25-000020.md) | [0.9](/filings/0000885590-25-000032.md) | [0.6](/filings/0000885590-25-000051.md) | [0.2](/filings/0000885590-26-000107.md) | [0.9](/filings/0000885590-26-000053.md) | [0.9](/filings/0000885590-26-000107.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [(1.2)](/filings/0000885590-23-000035.md) | [(1.0)](/filings/0000885590-25-000007.md) | [(1.1)](/filings/0000885590-24-000019.md) | [(1.2)](/filings/0000885590-24-000029.md) | [(1.2)](/filings/0000885590-24-000036.md) | [(1.3)](/filings/0000885590-26-000023.md) | [(1.2)](/filings/0000885590-25-000020.md) | [(0.8)](/filings/0000885590-25-000032.md) | [(0.6)](/filings/0000885590-25-000051.md) | [(0.6)](/filings/0000885590-26-000107.md) | [(2.1)](/filings/0000885590-26-000053.md) | [(1.8)](/filings/0000885590-26-000107.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [282 d](/filings/0000885590-24-000036.md) | [390 d](/filings/0000885590-26-000023.md) | [211](/filings/0000885590-25-000020.md) | [380 d](/filings/0000885590-25-000032.md) | [405 d](/filings/0000885590-25-000051.md) | [601 d](/filings/0000885590-26-000023.md) | [211](/filings/0000885590-26-000053.md) | [289 d](/filings/0000885590-26-000107.md) | [405 d](/filings/0000885590-25-000051.md) | [495 d](/filings/0000885590-26-000023.md) | [230](/filings/0000885590-26-000053.md) | [670 d](/filings/0000885590-26-000107.md) |
| Capital expenditure | $m | [42.0 d](/filings/0000885590-24-000036.md) | [98.0 d](/filings/0000885590-26-000023.md) | [82.0](/filings/0000885590-25-000020.md) | [78.0 d](/filings/0000885590-25-000032.md) | [71.0 d](/filings/0000885590-25-000051.md) | [106 d](/filings/0000885590-26-000023.md) | [115](/filings/0000885590-26-000053.md) | [99.0 d](/filings/0000885590-26-000107.md) | [91.0 d](/filings/0000885590-25-000051.md) | [92.0 d](/filings/0000885590-26-000023.md) | [109](/filings/0000885590-26-000053.md) | [77.0 d](/filings/0000885590-26-000107.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [363](/filings/0000885590-23-000035.md) | [363](/filings/0000885590-24-000019.md) | [367](/filings/0000885590-24-000029.md) | [365](/filings/0000885590-24-000036.md) | [367](/filings/0000885590-25-000020.md) | [370](/filings/0000885590-25-000032.md) | [368](/filings/0000885590-25-000051.md) | [370](/filings/0000885590-26-000053.md) | [373](/filings/0000885590-26-000107.md) | [376](/filings/0000885590-25-000051.md) | [373](/filings/0000885590-26-000053.md) | [378](/filings/0000885590-26-000107.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 373,990,561 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0000885590-26-000107.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.